166 related articles for article (PubMed ID: 36791561)
1. Significance of miRNAs on the thyroid cancer progression and resistance to treatment with special attention to the role of cross-talk between signaling pathways.
Doghish AS; El-Mahdy HA; Ismail A; Hegazy M; Mokhtar MM; Elkhawaga SY; Elkady MA; Yehia AM; Elsakka EGE
Pathol Res Pract; 2023 Mar; 243():154371. PubMed ID: 36791561
[TBL] [Abstract][Full Text] [Related]
2. miRNAs as potential game-changers in melanoma: A comprehensive review.
Abd-Allah GM; Ismail A; El-Mahdy HA; Elsakka EGE; El-Husseiny AA; Abdelmaksoud NM; Salman A; Elkhawaga SY; Doghish AS
Pathol Res Pract; 2023 Apr; 244():154424. PubMed ID: 36989843
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway.
Liu C; Feng Z; Chen T; Lv J; Liu P; Jia L; Zhu J; Chen F; Yang C; Deng Z
Cell Cycle; 2019 Jan; 18(2):167-203. PubMed ID: 30596336
[TBL] [Abstract][Full Text] [Related]
5. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
[TBL] [Abstract][Full Text] [Related]
7. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
[TBL] [Abstract][Full Text] [Related]
8. An emphasis on the interaction of signaling pathways highlights the role of miRNAs in the etiology and treatment resistance of gastric cancer.
Fathi D; Elballal MS; Elesawy AE; Abulsoud AI; Elshafei A; Elsakka EGE; Ismail A; El-Mahdy HA; Elrebehy MA; Doghish AS
Life Sci; 2023 Jun; 322():121667. PubMed ID: 37023952
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer.
Geraldo MV; Yamashita AS; Kimura ET
Oncogene; 2012 Apr; 31(15):1910-22. PubMed ID: 21874046
[TBL] [Abstract][Full Text] [Related]
10. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K/AKT pathway in papillary thyroid carcinoma.
Zheng T; Zhou Y; Xu X; Qi X; Liu J; Pu Y; Zhang S; Gao X; Luo X; Li M; Wang X; Dong L; Wang Y; Mao C
J Transl Med; 2022 Jan; 20(1):20. PubMed ID: 34991623
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma.
Petrulea MS; Plantinga TS; Smit JW; Georgescu CE; Netea-Maier RT
Cancer Treat Rev; 2015 Sep; 41(8):707-13. PubMed ID: 26138515
[TBL] [Abstract][Full Text] [Related]
12. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.
Shen CT; Qiu ZL; Song HJ; Wei WJ; Luo QY
J Exp Clin Cancer Res; 2016 Jun; 35(1):101. PubMed ID: 27342319
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway.
Bi CL; Zhang YQ; Li B; Guo M; Fu YL
J Cell Physiol; 2019 Apr; 234(4):4054-4067. PubMed ID: 30206929
[TBL] [Abstract][Full Text] [Related]
14. LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/β-Catenin Signaling.
Wang X; Lu X; Geng Z; Yang G; Shi Y
J Cell Biochem; 2017 Dec; 118(12):4745-4752. PubMed ID: 28513866
[TBL] [Abstract][Full Text] [Related]
15. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
16. Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review.
Ismail A; El-Mahdy HA; Abulsoud AI; Sallam AM; Eldeib MG; Elsakka EGE; Zaki MB; Doghish AS
Int J Biol Macromol; 2023 Jan; 224():1541-1565. PubMed ID: 36328268
[TBL] [Abstract][Full Text] [Related]
17. Roles of the SNHG7/microRNA‑9‑5p/DPP4 ceRNA network in the growth and
Chen W; Yu J; Xie R; Zhou T; Xiong C; Zhang S; Zhong M
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649840
[TBL] [Abstract][Full Text] [Related]
18. miRNA‑148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways.
Xu Y; Han YF; Zhu SJ; Dong JD; Ye B
Oncol Rep; 2017 Nov; 38(5):3085-3093. PubMed ID: 28901486
[TBL] [Abstract][Full Text] [Related]
19. Expression of MicroRNAs in Thyroid Carcinoma.
Zhu G; Xie L; Miller D
Methods Mol Biol; 2017; 1617():261-280. PubMed ID: 28540691
[TBL] [Abstract][Full Text] [Related]
20. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
